FDA Appoints New Chief Scientist - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Appoints New Chief Scientist


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Rockville, MD (Apr. 9)—The US Food and Drug Administration appointed Frank M. Torti, MD, MPH, as principal deputy commissioner and chief scientist. Torti’s appointment with FDA will begin in May.

The position of chief scientist is a new post created as a part of the Food and Drug Administration Amendments Act of 2007 and is designed to “ensure the quality and regulatory focus of the intramural research programs of the agency and place special emphasis on the importance of clinical research trials that are a part of the foundation of the FDA’s regulatory structure,” the agency said in a press release.

Torti has a background in molecular oncology and is chair of the Department of Cancer Biology and director of the Comprehensive Cancer Center at Wake Forest University School of Medicine. Torti received his medical degree from Harvard Medical School and his Master of Public Health from Harvard School of Public Health. Torti has served on several health and medical committees. FDA Commissioner Andrew C. von Eschenbach, stated “Dr. Torti’s impressive clinical and scientific credentials are an excellent match for the work we do on a daily basis to promote and protect the nation’s health as a science-based and science-led agency,” in a press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here